Oriol Mirallas MD· @DrMirallas · X·· 2026-04-20Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
Chinese groups are not short of G12C molecules (elisrasib’s floor numbers are strong).
Body
#AACR26
New frontiers in oncology
Elisrasib 2/3L #NSCLC #KRASG12C
@cbcbc1971
ORR 59.5% 2L naive
ORR 32.3% 3L refractari
KRASampl ORR 60%
STK11/KEAP1mut ORR 55 vs 71%
New player #KRASG12C
Going to 1L in comb CT+IO
By
@DocSacher
@OncoAlert
@AACR
Heat 58 · 43 likes · 2 replies · 13 reposts
Conference abstracts
Kanwal Pratap Raghav, Jun Zhang, Myung-Ah Lee, Jingdong Zhang, John Park, Yanqiao Zhang, Susana Rosello Keranen, Byoung Chul Cho, Herbert Ho Fung Loong, Cheng Chen, Huan Li, Shaonan Wang, Yandong Shen, Zifei Fan, Qian Chen, Hui Wang, Jing Zhang, George Zhi Jian Chen, Jayesh Desai, Antoine Hollebecque
Read the abstract →Source: Oriol Mirallas MD · x.com